Bio & Pharma
Celltrion's Remsima SC breaks 20% market share in Europe
This is the first time since the local launch in 2020 that a customized sales strategy for each country was effective
By 3 HOURS AGO
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO seeks restructuring for $1.9 bn injection in battery materials
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
GIC taps its real estate expert Jasmine Loo as new Korea head
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Doosan Robotics to delist, wholly own cash-cow Doosan Bobcat
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Samsung to mass-produce HBM4 on 4 nm foundry process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Celltrion's Remsima SC breaks 20% market share in Europe](https://www.kedglobal.com/data/ked/image/2024/07/17/ked202407170019.647x.0.jpg)
South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed a 20% market share in Europe during the first quarter of this year.
Launched in 2020 as a subcutaneous formulation of its blockbuster drug Remsima, Remsima SC offers patients a convenient alternative to the previous intravenous version.
The new formulation can be self-administered every two weeks in 10 seconds, compared to the hospital-based administration required by the IV version.
According to Celltrion and market research firm IQVIA, Remsima SC achieved a 21% market share across Europe in the first quarter, marking the first time it has crossed the 20% threshold.
The company attributed the success to its country-specific sales strategies, particularly in Germany and France.
Germany, where Remsima SC commands nearly 40% of the market.
Celltrion's German subsidiary has focused on building relationships with hospitals of all sizes to secure supply channels.
France, 28% of Remsima SC's European sales, has seen the company adopt a dual formulation strategy.
This involves transitioning patients from competing products to the IV version of Remsima before switching them to Remsima SC, leveraging a tender win with major procurement organization UniHA.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
-
-
Bio & PharmaCelltrion Healthcare's Remsima SC to be launched in US in 2024
Nov 30, 2023 (Gmt+09:00)
1 Min read -
-
Bio & PharmaCelltrion’s Remsima SC praised in Europe as preferred biosimilar
Jun 02, 2023 (Gmt+09:00)
2 Min read
Comment 0
LOG IN